|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Padlock Therapeutics, Inc.
| | | Phone: | (978) 381-9601 | Year Established: | 2014 | Ticker: | NYSE | Exchange: | BMY | Main Contact: | Samantha Truex, CBO | | Other Contacts: | Mariana Nacht, Ph.D., head of Biology Rajesh Devraj, Ph.D., CSO Michael Gilman, Ph.D., CEO & Founder
| | Company Description | Padlock Therapeutics is a privately--based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. The company leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. Padlock was founded by scientists at The Scripps Research Institute in conjunction with Atlas Venture. Padlock’s Series A investors include Atlas Venture, Johnson & Johnson Innovation – JJDC, Inc., MS Ventures, and Index Ventures.
On March 22, 2016, Bristol-Myers Squibb and Padlock Therapeutics announced an agreement whereby Bristol-Myers will acquire all of the outstanding capital stock of Padlock for milestone payments of up to $225 million and additional contingent consideration of up to $375 million. | |
|
|
|
|
|